Navigation Links
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Date:9/21/2009

e world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Forward-Looking Statements

This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 21, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candid
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Legislation backed by the drugstore ... Pharmacies Act of 2014") championing so-called "any willing ... the availability of lower cost preferred pharmacy networks ... the next 10 years, according to new research ... Care Management Association (PCMA). The drugstore ...
(Date:7/22/2014)... , July 22, 2014  Eyeon Therapeutics has received ... treatment based on a charged hydrophilic polymer developed at ... has been shown to be safe and effective in ... MD, CEO states, "This first set of claims around ... way to moving this technology into the commercial phase.  ...
(Date:7/22/2014)... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and ... lots of Fluzone ® (Influenza Vaccine) for the 2014-2015 ... Food and Drug Administration (FDA) for distribution. The lots were ... least 65 million doses of seasonal influenza vaccine manufactured by ... providers and pharmacies in August. The U.S. ...
Breaking Medicine Technology:New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7
... Aug. 17 The hospital patient room of the future ... New Jersey, providing lessons that stand to benefit hospitals and ... building a new hospital in Plainsboro, NJ, to replace its ... a fully functioning replica of the new hospital,s proposed patient ...
... Inc. (NYSE Amex: ULU ) today announced its financial ... the second quarter of 2010, the Company reported a net loss of ... $2.9 million, or $0.04 per share, for the same period last year. ... net loss of $3.5 million, or $0.04 per share, compared with a ...
Cached Medicine Technology:Hospital Room of the Future Debuts in New Jersey 2Hospital Room of the Future Debuts in New Jersey 3Hospital Room of the Future Debuts in New Jersey 4ULURU Inc. Reports Second Quarter 2010 Financial Results 2ULURU Inc. Reports Second Quarter 2010 Financial Results 3ULURU Inc. Reports Second Quarter 2010 Financial Results 4ULURU Inc. Reports Second Quarter 2010 Financial Results 5ULURU Inc. Reports Second Quarter 2010 Financial Results 6
(Date:7/22/2014)... Dr. Dental is excited to announce the ... visitors in mind, one of the main differences from the ... makes navigation very easy. Dr. Dental is renowned for having ... the dentist affordable, convenient and fun, and the new website ... an appointment scheduling system right on the home page where ...
(Date:7/22/2014)... 22, 2014 The 2014 Warrior-Family ... Ronald Reagan Building and International Trade Center in ... Families and Civilian Communities,” will be held from ... 7:30 a.m.) and cohosted by the Military Officers ... Industrial Association (NDIA). USAA is the Executive Sponsor ...
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will serve ... for the 2014-2015 fiscal year. He joined the Board ... "“Serving on the HASA board has given me a broader, ... remember how much others need help." , ABOUT AARON MARSHALL:, ... a B.S. in Finance from the University of Delaware. Currently, ...
(Date:7/22/2014)... Steven Reinberg HealthDay ... Two treatments that break up blood clots deep in the ... death risk. However, one results in a greater risk of ... cost of the other treatment, a new study finds. ... vein thrombosis (DVT) -- is blood-thinning medications and compression stockings. ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor ... Los Angeles with the 2014 E. Donnall Thomas ... the discovery of the iron-regulatory hormone hepcidin and investigation ... after the Nobel Prize Laureate and past Society president ... hematology that have represented a paradigm shift or significant ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:New Board President for Baltimore-based Nonprofit 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3
... at Telemedicine Conference in Las Vegas, Booth 1206 LAS ... Suisse AG (Fora Care,s Swiss sister company) announced today ... American Telemedicine Association (ATA) conference through April 28 at ... The veteran telemedicine companies are presenting at the ...
... following is being issued by American Stroke Association: , , ... It,s better to find out than miss out. Be aware ... and their side effects. Ask if your home should be modified ... doctor, nurse or therapist to clarify any unanswered questions or to ...
... Daily exposure to toxins in the products we ... insecticides, are creating a toxic load on our bodies ... In light of increased awareness of our environmental exposures, ... ) announced today the release of three new testing ...
... campaign reflects diverse communities; focuses on health advocacy ... Kaiser Permanente is adding two new television commercials ... campaign this month. The 30-second ads, titled "Mural" ... communities it serves, as well as the organization,s ...
... painful flare-ups, study finds , , MONDAY, April 27 (HealthDay ... and inexpensive way of treating children with eczema, according ... 17 percent of school-age children, can affect youngsters, appearance, ... , Eczema-related itching can be so bad that children ...
... have a ,baseline, prostate cancer screen at 40, but yearly ... 27 (HealthDay News) -- New guidelines on prostate cancer screening ... for many men, but the same guidelines call for a ... 50. , A prostate-specific antigen (PSA) test to detect early ...
Cached Medicine News:Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 2Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 3Health News:15 Tips Caregivers Should Know After a Loved One Has Had a Stroke 2Health News:15 Tips Caregivers Should Know After a Loved One Has Had a Stroke 3Health News:Metametrix Announces New Toxic Effects Profiles to Help Combat Growing Concerns About Toxicity and Health 2Health News:Kaiser Permanente Continues to Spread Health With New Ads Debuting in April 2Health News:Kaiser Permanente Continues to Spread Health With New Ads Debuting in April 3Health News:Diluted Bleach Baths Ease Kids' Eczema 2Health News:Experts Back Away From Annual PSA Test 2Health News:Experts Back Away From Annual PSA Test 3
... matrix constructed of cross-linked collagen fibers ... through a proprietary 360 accretion process. ... aspirate, Healos provides an excellent environment ... differentiation. The hydroxyapatite-coated collagen microfibers in ...
Sharp Weitlaner Retractor....
Weitlaner retractor, blunt....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
Medicine Products: